Keywords: up, 448m, govt, biothrax, contract, emergent, biosolutions

Up to $448M US govt BioThrax contract

Article | 6 October 2008

Emergent BioSolutions that it has signed a new, multi-year, firm fixed price contract with the US Department of Health and Human Services to supply an additional 14.5 million doses of BioThrax (anthrax vaccine adsorbed), its Food and Drug Administration-licensed anthrax vaccine, for inclusion in the Strategic National Stockpile.

The total value of this follow-on contract is between $364.0 million and $404.0 million, with the higher amount tied to the delivery of product having four-year expiry dating. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in